Recent articles

In 2021, EMA published a favourable advisory report on the benefit-risk balance of the drug icosapent ethyl (EPA), branded as Vazkepa®, after which it was authorised for use in Europe. A large ran ...

Summary Drovelis®, a contraceptive pill containing the new oestrogen estetrol, was recently authorised for the European market by EMA. The reliability of this pill, which combines estetrol with d ...

The use of drugs can affect the thyroid’s functioning, which can lead to hypothyroidism, hyperthyroidism or, in severe cases, to thyrotoxicosis. This involves various mechanisms, including changes ...

Systematic reviews and meta-analyses (including network meta-analyses) are increasingly being updated and are evolving into ‘living systematic reviews’ (LSRs). As a result of rapid developments in ...

An elevated LDL-cholesterol concentration is one of the risk factors for atherosclerotic vascular disease that can be modified by lifestyle interventions or medication. Due to their greatly elevat ...

Summary The polypill, a combination therapy to prevent cardiovascular diseases like myocardial infarction, does not yet appear to be a wonder drug. Research into primary prevention using a polypi ...

The first of a series of three articles on the influence of drugs on the thyroid gland discusses the influence that drugs can have on the findings of laboratory assessments of thyroid values. It p ...

As a consequence of the publication of a number of randomised studies, Semaglutide has recently received much publicity as a possible treatment of obesity. In the Netherlands, semaglutide had been ...